Company
Verona Pharma
LON:VRP
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.
58 stories
Verona Pharma to present COPD drug data to leading conference
Delegates at the virtual European Respiratory Society International Congress will be provided subgroup analysis from Verona’s phase IIb trials of nebulised ensifentrine
Small Cap Feast featuring Kibo Energy, Oriole Resources, Ironridge Resources and others
What’s cooking in the IPO kitchen? Aberdeen Frontier Markets Investment Company has left AIM following a Members Voluntary Liquidation
Verona Pharma kicks off second part of phase II trial assessing potential of COPD drug used in a pressurised metered-dose inhaler
Results from the multi-dose assessment are expected in the first half of 2021
Verona Pharma primed for a busy second half
Being eagerly tracked by investors is the status of the ENHANCE phase III study of the treatment delivered using a nebuliser to people with chronic obstructive pulmonary disease
Archive
FTSE 100 gains a shade on week but closes firmly lower on Friday as China and US data disappoints
The UK's index of the largest shares closed down over 95 points on the day, or 1.55% at 6,090
Investments and investor services
Quiet Friday should allow greater attention on small caps
Delayed numbers had been expected by car dealer Lookers but this was due to a mistake on its website
Verona Pharma swims against the current with astonishing fundraise
The junior biotech saw its share price soaring following a fundraise worth double its market capitalisation. What made it so successful?
Archive
Proactive news headlines: Verona Pharma, ClearStar, Xpediator, Remote Monitored Systems …
A glance at some of the day's highlights from the Proactive Investors newswire
Verona Pharma raises US$200mln from oversubscribed private placement and subscription
The cash will be used to fund Verona’s phase III ENHANCE clinical programme for the inhaled nebulised drug, ensifentrine
Verona Pharma looks forward to phase III ensifentrine trials after US$200mln fundraise
The US authorities gave the green light to conduct the final phase of trials
Verona Pharma given US regulatory go ahead for phase III programme
The two-part programme will assess the efficacy of the company's drug ensifentrine when administered to patients with chronic obstructive pulmonary disease using a drug delivery device called a nebuliser
Verona Pharma has six abstracts accepted for industry conference and published in peer-reviewed journal
The data will be showcased at the American Thoracic Society's annual conference
Verona Pharma prepares for responses from US regulator after a busy three months
The company is focused developing discoveries such as ensifentrine for respiratory conditions such as chronic obstructive pulmonary disease
Verona Pharma phase II drug delivered “statistically significant and clinically meaningful” increases in lung function
The trial of 40 moderate to severe chronic obstructive pulmonary disease patients assessed ensifentrine’s potential when delivered via pressurised metered-dose inhalers similar to the ones used by asthmatics
Verona Pharma confident 2020 will be a transformational year
Verona is in Phase 2 development with three formulations of ensifentrine for COPD: nebulised, dry powder inhaler and pressurised metered-dose inhaler
Archive
Proactive news snapshot: Verona Pharma, SDX Energy, Europa Metals, Chesnara …
A glance at some of the day's highlights from the Proactive Investors newswire
Verona Pharma COPD trial results carried in scientific journal
Respiratory Research carried the data from Verona’s four-week, 400-patient study first released in 2018
Verona Pharma draft in two new "highly experienced" execs to lead the business into the next phase
David Zaccardelli has replaced Jan-Anders Karlsson as chief executive, while Mark Hahn has been brought in as chief financial officer
Archive
Proactive news snapshot: Verona Pharma, Anglo African Oil & Gas, Faron Pharmaceuticals, KRM22 …
A glance at some of the day's highlights from the Proactive Investors newswire
Verona Pharma shares jump after COPD study delivers "impressive" results
Gary Ferguson, who led the four-week study of 416 people with chronic obstructive pulmonary disease, said: “The strong effect on both bronchodilation and quality of life as an add-on to tiotropium is impressive and consistent with prior stu
Verona Pharma appoints investor relations specialist to develop company's profile
David Moskowitz, who held similar positions at Trovagene and Biocept, has been appointed to the newly created role
Verona Pharma chief excited by COPD drug's potential
“We believe ensifentrine, with its unique dual mode of action and bronchodilator and anti-inflammatory properties, has the potential to become an important additional treatment option for many of these patients,” said CEO Jan-Anders Karlsso
Verona Pharma expects data from clinical trial around the end of the year
The phase IIb study will assess the safety and efficacy of its inhaled treatment for obstructive pulmonary disease
Verona Pharma to use industry conference to expand on lung disease treatment data
Chief medical officer Kathleen Rickard will present the new information on nebulised ensifentrine at the CHEST Annual Meeting in New Orleans
Verona Pharma PLC excited about the progress of ensifentrine through clinical trials
Recent trial results support the view that the drug could be an effective bronchodilator in COPD patients via various delivery methods
Verona Pharma: The AIM-quoted drug developer built on the research of a Glaxo legend
Sir David Jack's team were responsible for the discovery of several huge drugs, and RPL554, a compound he helped develop later on in his career, is now being taken through the clinic by Verona
Investments and investor services
FTSE 100 closes firmly in red as traders fret about trade
Stock markets in Europe have suffered severe declines as US-China trade tensions have heightened
Verona Pharma pushing ahead with development of lead drug despite recent splutter
Verona’s COPD treatment, ensifentrine, failed to meet the primary endpoint in a Phase 2 trial last month, but the results were encouraging enough for the company to keep the faith
Verona Pharma splutters as lead COPD drug disappoints in Phase II study
Ensifentrine was shown to be more effective than a placebo, although it didn’t improve patients’ breathing by as much as hoped
Archive
US midterm elections, Primark, Morrisons and Imperial Brands make for busy day ahead
The day ahead will see Americans go to the polls to vote in the midterm elections but closer to home the focus is on financials from AB Foods, Morrison's and Imperial Brands
A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles
Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target
Arix Biosciences making progress as well as adding value
Three of Arix's investee companies will be busy in the coming months, while a fourth now has the financial runway to expand its ground-breaking research
Archive
Other financials to take up the results mantle, with Standard Life Aberdeen and Hargreaves Lansdown due on Tuesday
Aside from the two financial blue chips, updates are also due on Tuesday from FTSE 100-listed InterContinental Hotels, and FTSE 250-listed Domino's Pizza
Arix Biosciences' progress significantly undervalued, suggests US broker
Arix’s portfolio companies are involved in 15 clinical trials
Verona Pharma's chief medical officer to quit at the end of the month
The search is already underway for Kenneth Newman's replacement
Milestone Group jumps as digital media company enters blockchain joint venture agreement
A look at some of the biggest risers and fallers in London on Monday
REACT Group plc cleaning up after another contract win for major hospital
Proactive takes a look at some movers and shakers throughout the day in London
Archive
Paddy Power Betfair and the final hurdle for CEO Breon Corcoran
Is Corcoran leaving on a high or getting out while the going's good?
Archive
A kick in the gear-box for insurers but great news for personal injury victims
Trending: Car insurers dented ; EU to kibosh German takeover of iconic UK organisation; Persimmon blooms; Verona blossoms
Riser and fallers: Laird, Travis Perkins, Highland...
Highland shares got a boost after the company successfully proved the effectiveness of its DT Ultravert 'anti-bashing' technology
London stocks hold onto gains as Brexit fears fade
The FTSE100 held onto most of its intraday gains to close over 3% higher on Monday after sentiment towards remaining in the EU grew
Risers & Fallers: Ascent Resources, Hummingbird, Mkango ...
The European oil and gas exploration and production company Ascent lived up to its name as resolutions 1 to 3 were duly passed at today’s AGM.
NASDAQ listing for Verona Pharma?
Shares rose more than 20% after an oversubscribed placing raised £44.7mln to fund its lung disease drug.
FTSE 100 up 2% as 'remain' camp builds head of steam
The FTSE 100 opened strongly as predicted, with the opinion polls suggesting the ‘remain campaign’ has a narrow lead ahead of the crucial vote on Thursday.
Ireland-focused oil firms boosted as FTSE 100 Index rises
The FTSE 100 Index closed 24.02 points up at 6209.63
Verona Pharma reports progress but losses rise
Drug group reported progress in developing its lung disease treatment
Investments and investor services
Aim 100 edges higher while the Footsie takes a dip
The Footsie followed Asia's lead after the BoJ left its policies unchanged, but Aim moved higher, led by Sirius Minerals
Investments and investor services
Risers & Fallers: Findel, Sports Direct, Sovereign Mines of Africa, Alexander Mining, Cyan Holdings
Below are the main news-driven share price movements at 3.30pm.
Tuesday's agenda: Berkeley kicks off busy week for housebuilders
Berkeley and Whitbread are scheduled to release trading updates on Tuesday,
Investments and investor services
Risers & fallers: Hardide, Mobile Streams, Auhua Clean Energy, Verona Pharma
Auhua Energy rebounded while Urals Energy jumped ahead of its final results on Friday.